Janux Therapeutics JANX Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- Janux Therapeutics (JANX) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $904.56M in Q1 2026.
- How has Janux Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
- Janux Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 3.8% year-over-year, from $940.4M to $904.56M.
- What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
- This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.